Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing.

Ishihara J, Ishihara A, Starke RD, Peghaire CR, Smith KE, McKinnon TAJ, Tabata Y, Sasaki K, White MJV, Fukunaga K, Laffan MA, Lutolf MP, Randi AM, Hubbell JA.

Blood. 2019 Jun 13;133(24):2559-2569. doi: 10.1182/blood.2019000510. Epub 2019 Apr 11.

PMID:
30975637
2.

ADAMTS-13 glycans and conformation-dependent activity.

Nowak AA, O'Brien HER, Henne P, Doerr A, Vanhoorelbeke K, Laffan MA, McKinnon TAJ.

J Thromb Haemost. 2017 Jun;15(6):1155-1166. doi: 10.1111/jth.13688. Epub 2017 Apr 27.

3.

N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance.

Chion A, O'Sullivan JM, Drakeford C, Bergsson G, Dalton N, Aguila S, Ward S, Fallon PG, Brophy TM, Preston RJ, Brady L, Sheils O, Laffan M, McKinnon TA, O'Donnell JS.

Blood. 2016 Oct 13;128(15):1959-1968. Epub 2016 Aug 23.

4.

Contrast-Enhanced Ultrasound for Thrombus Dissolution in an In Vitro Model of Acute Deep Venous Thrombosis.

Dharmarajah B, McKinnon TA, Keravnou C, Averkiou MA, Leen EL, Davies AH.

J Vasc Surg Venous Lymphat Disord. 2015 Jan;3(1):121. doi: 10.1016/j.jvsv.2014.10.017. Epub 2014 Dec 15. No abstract available.

PMID:
26993704
5.

Solution structure of the major factor VIII binding region on von Willebrand factor.

Shiltagh N, Kirkpatrick J, Cabrita LD, McKinnon TA, Thalassinos K, Tuddenham EG, Hansen DF.

Blood. 2014 Jun 26;123(26):4143-51. doi: 10.1182/blood-2013-07-517086. Epub 2014 Apr 3.

6.

The O-linked glycans of human von Willebrand factor modulate its interaction with ADAMTS-13.

Nowak AA, McKinnon TA, Hughes JM, Chion AC, Laffan MA.

J Thromb Haemost. 2014 Jan;12(1):54-61. doi: 10.1111/jth.12451.

7.

Circulating but not immobilized N-deglycosylated von Willebrand factor increases platelet adhesion under flow conditions.

Fallah MA, Huck V, Niemeyer V, Desch A, Angerer JI, McKinnon TA, Wixforth A, Schneider SW, Schneider MF.

Biomicrofluidics. 2013 Aug 26;7(4):44124. doi: 10.1063/1.4819746. eCollection 2013.

8.

The von Willebrand factor predicted unpaired cysteines are essential for secretion.

Shapiro SE, Nowak AA, Wooding C, Birdsey G, Laffan MA, McKinnon TA.

J Thromb Haemost. 2014 Feb;12(2):246-54. doi: 10.1111/jth.12466.

9.

Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells.

Starke RD, Paschalaki KE, Dyer CE, Harrison-Lavoie KJ, Cutler JA, McKinnon TA, Millar CM, Cutler DF, Laffan MA, Randi AM.

Blood. 2013 Apr 4;121(14):2773-84. doi: 10.1182/blood-2012-06-435727. Epub 2013 Jan 25.

10.

Identification of functionally important residues in TFPI Kunitz domain 3 required for the enhancement of its activity by protein S.

Ahnström J, Andersson HM, Hockey V, Meng Y, McKinnon TA, Hamuro T, Crawley JT, Lane DA.

Blood. 2012 Dec 13;120(25):5059-62. doi: 10.1182/blood-2012-05-432005. Epub 2012 Oct 16.

PMID:
23074276
11.

Mapping the N-glycome of human von Willebrand factor.

Canis K, McKinnon TA, Nowak A, Haslam SM, Panico M, Morris HR, Laffan MA, Dell A.

Biochem J. 2012 Oct 15;447(2):217-28.

12.

Characterisation of von Willebrand factor A1 domain mutants I1416N and I1416T: correlation of clinical phenotype with flow-based platelet adhesion.

McKinnon TA, Nowak AA, Cutler J, Riddell AF, Laffan MA, Millar CM.

J Thromb Haemost. 2012 Jul;10(7):1409-16. doi: 10.1111/j.1538-7836.2012.04760.x.

13.

O-linked glycosylation of von Willebrand factor modulates the interaction with platelet receptor glycoprotein Ib under static and shear stress conditions.

Nowak AA, Canis K, Riddell A, Laffan MA, McKinnon TA.

Blood. 2012 Jul 5;120(1):214-22. doi: 10.1182/blood-2012-02-410050. Epub 2012 Apr 19.

PMID:
22517896
14.

Endothelial von Willebrand factor regulates angiogenesis.

Starke RD, Ferraro F, Paschalaki KE, Dryden NH, McKinnon TA, Sutton RE, Payne EM, Haskard DO, Hughes AD, Cutler DF, Laffan MA, Randi AM.

Blood. 2011 Jan 20;117(3):1071-80. doi: 10.1182/blood-2010-01-264507. Epub 2010 Nov 3.

15.

Specific N-linked glycosylation sites modulate synthesis and secretion of von Willebrand factor.

McKinnon TA, Goode EC, Birdsey GM, Nowak AA, Chan AC, Lane DA, Laffan MA.

Blood. 2010 Jul 29;116(4):640-8. doi: 10.1182/blood-2010-02-267450. Epub 2010 Apr 23.

PMID:
20418283
16.

Expression of terminal alpha2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13.

McGrath RT, McKinnon TA, Byrne B, O'Kennedy R, Terraube V, McRae E, Preston RJ, Laffan MA, O'Donnell JS.

Blood. 2010 Apr 1;115(13):2666-73. doi: 10.1182/blood-2009-09-241547. Epub 2009 Nov 24.

PMID:
19965639
17.

The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs.

Canis K, McKinnon TA, Nowak A, Panico M, Morris HR, Laffan M, Dell A.

J Thromb Haemost. 2010 Jan;8(1):137-45. doi: 10.1111/j.1538-7836.2009.03665.x. Epub 2009 Oct 24.

18.

Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor.

Riddell AF, Gomez K, Millar CM, Mellars G, Gill S, Brown SA, Sutherland M, Laffan MA, McKinnon TA.

Blood. 2009 Oct 15;114(16):3489-96. doi: 10.1182/blood-2008-10-184317. Epub 2009 Aug 17.

PMID:
19687512
19.

A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF.

Zanardelli S, Chion AC, Groot E, Lenting PJ, McKinnon TA, Laffan MA, Tseng M, Lane DA.

Blood. 2009 Sep 24;114(13):2819-28. doi: 10.1182/blood-2009-05-224915. Epub 2009 Jul 8.

20.

Blocking von Willebrand factor: a novel anti-platelet therapy.

Laffan M, McKinnon TA.

J Thromb Haemost. 2009 Jul;7(7):1152-4. doi: 10.1111/j.1538-7836.2009.03480.x. Epub 2009 May 8. No abstract available.

21.

N-linked glycosylation of VWF modulates its interaction with ADAMTS13.

McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA.

Blood. 2008 Mar 15;111(6):3042-9. Epub 2007 Nov 1.

PMID:
17975018
22.

Intrinsic charge ladders of a monoclonal antibody in hydroxypropylcellulose-coated capillaries.

Sanzgiri RD, McKinnon TA, Cooper BT.

Analyst. 2006 Sep;131(9):1034-43. Epub 2006 Jul 6.

PMID:
17047804
23.

Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis.

O'Donnell JS, McKinnon TA, Crawley JT, Lane DA, Laffan MA.

Blood. 2005 Sep 15;106(6):1988-91. Epub 2005 May 10.

PMID:
15886321

Supplemental Content

Loading ...
Support Center